Literature DB >> 15389825

Second case of CML with aberrant BCR-ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron 1b sequence.

Takeshi Sugimoto1, Kentaro Ijima, Hisashi Hisatomi, Tohru Murayama, Ishikazu Mizuno, Akio Hato, Shion Imoto, Ryuichiro Nishimura, Tamio Koizumi.   

Abstract

We found a case of Ph-positive chronic myelogenous leukemia (CML) patient with an atypical BCR-ABL transcript that was undetectable by a routine reverse transcription polymerase chain reaction (RT-PCR) for major BCR-ABL. Additional RT-PCR and sequence analyses have demonstrated that the aberrant transcript consists of a fusion of BCR exon 8 (e8) and ABL exon 2 (a2) with an insertion of a 55-bp inverted sequence of intron 1b between them. The nucleotide sequences of the aberrant transcript were identical to those of a previously reported CML patient. These are the only two CML cases in the literature with identical aberrant BCR-ABL transcripts. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15389825     DOI: 10.1002/ajh.20138

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemia.

Authors:  Nathalie Sorel; Caroline Mayeur-Rousse; Séverine Deverrière; Lydia Roy; Elisabeth Brottier-Mancini; François Guilhot; Ali G Turhan; Jean Claude Chomel
Journal:  J Mol Diagn       Date:  2010-05-27       Impact factor: 5.568

2.  A combined computational and experimental strategy identifies mutations conferring resistance to drugs targeting the BCR-ABL fusion protein.

Authors:  Jinxin Liu; Jianfeng Pei; Luhua Lai
Journal:  Commun Biol       Date:  2020-01-09

3.  Characteristics of BCR-ABL gene variants in patients of chronic myeloid leukemia.

Authors:  Huma Amin; Suhaib Ahmed
Journal:  Open Med (Wars)       Date:  2021-06-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.